Paper Details

  1. Home
  2. Paper Details

Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.

Author: , CooperCurtis, FainboimHugo, GreavesWayne, HoweAnita Y M, MakCarmen, MallolasJosep, PolStanislas, RiveroAntonio, SklarPeter, SlimJihad, SulkowskiMark, ThompsonSeth, WahlJanice, WenningLarissa

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study aimed to assess the efficacy and safety of triple therapy with boceprevir, peginterferon alfa-2b, and ribavirin in patients with hepatitis C virus (HCV) genotype 1 and HIV.
Paper Details　
Original Abstract of the Article :
Rates of sustained virological response (SVR) to peginterferon-ribavirin are low in patients with hepatitis C virus (HCV) genotype 1 and HIV. We aimed to assess efficacy and safety of triple therapy with boceprevir plus pegylated interferon alfa-2b (peginterferon) and ribavirin, which increases rate...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S1473-3099(13)70149-X

データ提供：米国国立医学図書館（NLM）

Boceprevir: A Hope for Hepatitis C Treatment in HIV-Positive Individuals

The world of viral infections is complex, and co-infections present unique challenges for treatment. This research focuses on the effectiveness and safety of boceprevir, a drug used to treat hepatitis C virus (HCV) genotype 1, in patients also living with HIV. The study aimed to evaluate the efficacy of triple therapy, combining boceprevir with pegylated interferon alfa-2b and ribavirin, in this challenging patient population. This research employed a randomized, double-blind, controlled phase 2 trial to rigorously assess the effects of boceprevir in individuals with both HIV and HCV.

Boceprevir: A Potential Breakthrough in Co-Infection Treatment

The study showed promising results. Boceprevir, in combination with pegylated interferon alfa-2b and ribavirin, demonstrated the potential to increase the rates of sustained virological response (SVR), indicating the complete eradication of HCV, in patients with both HIV and HCV genotype 1. This finding holds significant promise for improving the treatment outcomes for this vulnerable population. The research underscores the importance of exploring new therapeutic strategies for co-infections to address the unique challenges they pose to patient care.

A New Horizon for Co-Infected Patients

This study sheds light on a potential breakthrough in the treatment of co-infections. By demonstrating the efficacy of boceprevir in patients with both HIV and HCV, this research offers hope for a more effective and comprehensive treatment approach. This advancement could significantly improve the lives of individuals struggling with these complex infections, offering them a brighter future.

Dr.Camel's Conclusion

Navigating the complexities of co-infections is like navigating a sandstorm. This research offers a ray of hope, illuminating a potential pathway for treating hepatitis C in individuals living with HIV. The study highlights the importance of continued research in finding effective and safe treatments for co-infections, bringing us closer to a future where these challenges are no longer insurmountable.

Date :
  1. Date Completed 2013-09-04
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

23768747

DOI: Digital Object Identifier

10.1016/S1473-3099(13)70149-X

Related Literature

Article Analysis
・Side Effects of boceprevir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.